DURHAM, N.C.--(BUSINESS WIRE)--Tryton Medical, Inc., the leading developer of stents designed to definitively treat bifurcation lesions, today announced interim six-month results from the company’s E-Tryton registry evaluating the TRYTON Side Branch Stent™ System at 15 European sites.
